В здравом уме и твердой памяти. Программа профилактики болезни Альцгеймера

Alzheimer’s Foundation of America survey. http://www.alzfdn.org/MediaCenter/073008.html.

Ginó, S., et al. “Memory complaints are frequent but qualitatively different in young and elderly healthy people.” Gerontology 56: (2010): 272–77.

Alzheimer’s Association. 2009 Alzheimer’s Disease Facts and Figures. http://www.alz.org/national/documents/report_alzfactsfigures2009.pdf.

Alzheimer’s Disease International. World Alzheimer’s Report 2010: The Global Economic Impact of Dementia. http://www.alz.org/documents/national/World_Alzheimer_Report_2010.pdf.

Rowe, J. W., and R. L. Kahn. “The future of aging.” Contemp Longterm Care 22 (1999): 36–44.

Graeber, M. B., et al. “Histopathology and APOE genotype of the first Alzheimer disease patient, Auguste D.” Neurogenetics 1 1998: 223–28.

Blessed, G., et al. “The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.” Br J Psychiatry 114 (1968): 797–811.

Daviglus, M. L., et al. NIH State-of-the-Science Conference Statement on Preventing Alzheimer’s Disease and Cognitive Decline. NIH Consens State Sci Statements 27 (2010): 1–30.

Braak, H., and E. Braak. “Neuropathological staging of Alzheimer-related changes.” Acta Neuropathol 82 (1991): 239–59.

Shoghi-Jadid, K., et al. “Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer’s disease.” Am J Geriatr Psychiatry 10 (2002): 24–35.

Small, G. W., et al. “PET of brain amyloid and tau in mild cognitive impairment.” N Engl J Med 355 (2006): 2652–63.

Small, G. W., et al. “Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.” Arch Gen Psychiatry 66 (2009): 81–87.

Ercoli, L. M., et al. “Differential FDDNP PET patterns in non-demented middle-aged and older adults.” Am J Geriatr Psychiatry 17 (2009): 397–406.

Petersen, R. C., et al. “Vitamin E and donepezil for the treatment of mild cognitive impairment.” N Engl J Med 352 (2005): 2379–88.

Petersen, R. C. “Mild cognitive impairment as a diagnostic entity.” J Int Med 256 (2004): 183–94.

Dubois, B., et al. “Revising the definition of Alzheimer’s disease: a new lexicon.” Lancet Neurol 9 (2010): 1118–27. “New Criteria and Guidelines for Alzheimer’s Disease Diagnosis.” Alzheim Dementia 2011. http://www.alzheimersanddementia.org/content/ncg.

Ritchie, K. “Eugeria, longevity and normal ageing.” Br J Psychiatry 171 (1997): 501.

Relkin, N. R., et al. “Apolipoprotein E genotyping in Alzheimer’s disease: Position statement of the National Institute on Aging/Alzheimer’s Association Working Group.” Lancet 347 (1996): 1091–95.

Ashida, S., et al. “The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study.” Eur J Hum Genet 18 (2010); 1296–1301.

Rowe, J. W., and R. L. Kahn. “The future of aging.” Contemp Longterm Care 22 (1999): 36–44.

Small G. W., et al. “Clinical, neuroimaging, and environmental risk differences in monozygotic female twins appearing discordant for dementia of the Alzheimer type.” Arch Neurol 50 (1993): 209–19.

Smith, A. D. “Why are drug trials in Alzheimer’s disease failing?” Lancet 376 (2010): 1466. Extance, A. “Alzheimer’s failure raises questions about disease-modifying strategies.” Nat Rev Drug Discov 9 (2010): 749–51.

Tomic, J. L., et al. “Soluble fibrillar oligomer levels are elevated in Alzheimer’s disease brain and correlate with cognitive dysfunction.” Neurobiol Dis 35 (2009): 352–58.

Stewart, W. F., et al. “Risk of Alzheimer’s disease and duration of NSAID use.” Neurology 48 (1997): 626–32.

Small, G. W., et al. “Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: Randomized controlled study.” Am J Geriatr Psychiatry 16 (2008): 999–1009.

Sonnen, J. A., et al. “Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques.” Neurology 75 (2010): 1203–10.

Breitner, J.C.S. and P. P. Zandi. “Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer’s disease?” N Engl J Med 345 (2001): 1567–78.

Jerdziewski, M. K., et al. “Lowering the risk of Alzheimer’s disease: Evidence-based practices emerge from new research.” Alzheimer Dement 1 (2005):152–60.

Rolland, Y., et al. “Healthy brain aging: Role of exercise and physical activity.” Clin Geriatr Med 26 (2010): 75–87.